FR2845385B1 - COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS - Google Patents

COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS

Info

Publication number
FR2845385B1
FR2845385B1 FR0212370A FR0212370A FR2845385B1 FR 2845385 B1 FR2845385 B1 FR 2845385B1 FR 0212370 A FR0212370 A FR 0212370A FR 0212370 A FR0212370 A FR 0212370A FR 2845385 B1 FR2845385 B1 FR 2845385B1
Authority
FR
France
Prior art keywords
thiohydantoin
therapeutics
compounds derived
derived
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0212370A
Other languages
French (fr)
Other versions
FR2845385A1 (en
Inventor
Benaissa Boubia
Khan Ou
Evelyne Chaput
Philippe Ratel
Jean Binet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Fournier SAS
Original Assignee
Laboratories Fournier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0212370A priority Critical patent/FR2845385B1/en
Application filed by Laboratories Fournier SAS filed Critical Laboratories Fournier SAS
Priority to PCT/FR2003/002904 priority patent/WO2004031160A2/en
Priority to JP2004540883A priority patent/JP2006510600A/en
Priority to CA002500977A priority patent/CA2500977A1/en
Priority to EP03772390A priority patent/EP1546111A2/en
Priority to US10/529,817 priority patent/US20060025589A1/en
Priority to AU2003279442A priority patent/AU2003279442A1/en
Publication of FR2845385A1 publication Critical patent/FR2845385A1/en
Application granted granted Critical
Publication of FR2845385B1 publication Critical patent/FR2845385B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
FR0212370A 2002-10-01 2002-10-04 COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS Expired - Fee Related FR2845385B1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0212370A FR2845385B1 (en) 2002-10-04 2002-10-04 COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS
JP2004540883A JP2006510600A (en) 2002-10-04 2003-10-03 Compounds derived from 2-thiohydantoin and their use in therapy
CA002500977A CA2500977A1 (en) 2002-10-04 2003-10-03 2-thiohydantoine derivative compounds and use thereof in therapeutics
EP03772390A EP1546111A2 (en) 2002-10-04 2003-10-03 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
PCT/FR2003/002904 WO2004031160A2 (en) 2002-10-04 2003-10-03 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
US10/529,817 US20060025589A1 (en) 2002-10-01 2003-10-03 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2003279442A AU2003279442A1 (en) 2002-10-04 2003-10-03 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0212370A FR2845385B1 (en) 2002-10-04 2002-10-04 COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS

Publications (2)

Publication Number Publication Date
FR2845385A1 FR2845385A1 (en) 2004-04-09
FR2845385B1 true FR2845385B1 (en) 2004-12-31

Family

ID=32011425

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0212370A Expired - Fee Related FR2845385B1 (en) 2002-10-01 2002-10-04 COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS

Country Status (1)

Country Link
FR (1) FR2845385B1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3412290B1 (en) 2006-03-27 2021-03-03 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AR102942A1 (en) 2014-12-11 2017-04-05 Bayer Cropscience Ag DERIVATIVES OF ARILSULFIDE AND ARILSULPHOXIDE OF FIVE C-N-CONNECTED MEMBERS, AS PESTICIDES
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE550650A (en) * 1955-08-30
AU531493B2 (en) * 1977-12-01 1983-08-25 The Wellcome Foundation Limited Thiohydantion derivatives
US4743611A (en) * 1986-07-02 1988-05-10 American Home Products Corp. Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
AU1127697A (en) * 1995-11-28 1997-06-19 American Home Products Corporation 2-thioxo-imidazolidin-4-one derivatives and their use for increasing hdl cholesterol concentration
ES2248107T3 (en) * 1999-08-31 2006-03-16 Incyte San Diego Incorporated BENCILIDEN-TIAZOLIDINDIONAS AND ANALOGS AND ITS USE IN THE TREATMENT OF DIABETES.

Also Published As

Publication number Publication date
FR2845385A1 (en) 2004-04-09

Similar Documents

Publication Publication Date Title
FR2823209B1 (en) NOVEL THIOHYDANTOINS AND THEIR USE IN THERAPEUTICS
MA28758B1 (en) AMINOALKYLGLUCOSAMINIDE PHOSPHATE COMPOUNDS AND USE THEREOF
IL164400A0 (en) Deruvatuves if n-Äphenyl(piperidin-2-yl)methylÜbenzamide, the preparation method thereof and application of same in therapeutics
EG23770A (en) Thin and dry diaper
PT2702871T (en) Collagen biofabric and use thereof
PT1419150E (en) 1-PHENYLSULPHONYL-1,3-DIHYDRO-2H-INDOL-2-ONA DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
MA26348A1 (en) SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINE AND THEIR USE
GB0401363D0 (en) Hinge unit and hinge structure using the same
DE60304737D1 (en) IMPROVEMENTS IN SMOKE ITEMS
DE60329138D1 (en) ATM
FR2845384B1 (en) COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS
FR2869217B1 (en) GLENOIDAL IMPLANT FOR TOTAL REVERSE SHOULDER PROSTHESIS, AND TOTAL REVERSE SHOULDER PROSTHESIS COMPRISING THE SAME
PT1513836E (en) PIPERAZINILACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
EP1689321A4 (en) Artificial tissue systems and uses thereof
GB0323954D0 (en) Block copolymer and use thereof
EP1700627A4 (en) Card game system and card used in the card system
GB2389501B (en) Game system and game program
NO20031332L (en) Arylalkanesulfonamides with endothelin antagonist activity
FR2845385B1 (en) COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS
FR2845383B1 (en) COMPOUNDS DERIVED FROM 2-THIOHYDANTOIN AND THEIR USE IN THERAPEUTICS
FR2838960B1 (en) COMPOSITION COMPRISING PHOTOCHROMES AND USE THEREOF IN COSMETICS
DE60019832D1 (en) Combined charging and cleaning blade
GB0526509D0 (en) Construction machine and projecting object of the same
NO990256D0 (en) Polymer blends, their preparation and use
AU2003228355A8 (en) Adipocytes and uses thereof

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20070629